Multiple myeloma is a malignant disease characterized with the aid of plasmacytosis, paraprotein production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the medical features include suppression of humoral- and cell-mediated immunity, elevation of IL-6, abnormalities of the bone marrow microenvironment, and elevated osteoclastic pastime. Overwhelming predictors of analysis include albumin, β2-microglobulin, and chromosomal karyotype. With current, extensive therapy which include autologous hematopoietic stem cellular transplantation, the median survival is about 5 year. The disorder is incurable and eventually relapses; requiring salvage therapy. The development of more recent marketers along with thalidomide, bortezomib, and lenalidomide—capsules that interfere with numerous of the complex pathophysiologic steps—has advanced the outlook of relapsed disorder substantially. Current studies are directed at exploring the usage of these novel retailers earlier inside the course of remedy, improvement of more recent targeted cures, and the usage of gene expression profiling to individualize remedy.